Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jin Hyang Kim is active.

Publication


Featured researches published by Jin Hyang Kim.


Journal of Immunology | 2009

Original Antigenic Sin Responses to Influenza Viruses

Jin Hyang Kim; Ioanna Skountzou; Richard W. Compans; Joshy Jacob

Most immune responses follow Burnet’s rule in that Ag recruits specific lymphocytes from a large repertoire and induces them to proliferate and differentiate into effector cells. However, the phenomenon of “original antigenic sin” stands out as a paradox to Burnet’s rule of B cell engagement. Humans, upon infection with a novel influenza strain, produce Abs against older viral strains at the expense of responses to novel, protective antigenic determinants. This exacerbates the severity of the current infection. This blind spot of the immune system and the redirection of responses to the “original Ag” rather than to novel epitopes were described fifty years ago. Recent reports have questioned the existence of this phenomenon. Hence, we revisited this issue to determine the extent to which original antigenic sin is induced by variant influenza viruses. Using two related strains of influenza A virus, we show that original antigenic sin leads to a significant decrease in development of protective immunity and recall responses to the second virus. In addition, we show that sequential infection of mice with two live influenza virus strains leads to almost exclusive Ab responses to the first viral strain, suggesting that original antigenic sin could be a potential strategy by which variant influenza viruses subvert the immune system.


Journal of Immunology | 2010

Immunity to Pre-1950 H1N1 Influenza Viruses Confers Cross-Protection against the Pandemic Swine-Origin 2009 A (H1N1) Influenza Virus

Ioanna Skountzou; Dimitrios G. Koutsonanos; Jin Hyang Kim; Ryan Powers; Lakshmipriyadarshini Satyabhama; Feda Masseoud; William C. Weldon; Maria del Pilar Martin; Robert S. Mittler; Richard W. Compans; Joshy Jacob

The 2009 H1N1 influenza virus outbreak is the first pandemic of the twenty-first century. Epidemiological data reveal that of all the people afflicted with H1N1 virus, <5% are over 51 y of age. Interestingly, in the uninfected population, 33% of those >60 y old have pre-existing neutralizing Abs against the 2009 H1N1 virus. This finding suggests that influenza strains that circulated 50–60 y ago might provide cross-protection against the swine-origin 2009 H1N1 influenza virus. To test this, we determined the ability of representative H1N1 influenza viruses that circulated in the human population from 1930 to 2000, to induce cross-reactivity to and cross-protection against the pandemic swine-origin H1N1 virus, A/California/04/09. We show that exposure of mice to the 1947 virus, A/FM/1/47, or the 1934 virus, A/PR/8/34, induced robust cross-protective immune responses and these mice were protected against a lethal challenge with mouse-adapted A/California/04/09 H1N1 virus. Conversely, we observed that mice exposed to the 2009 H1N1 virus were protected against a lethal challenge with mouse-adapted 1947 or 1934 H1N1 viruses. In addition, exposure to the 2009 H1N1 virus induced broad cross-reactivity against H1N1 as well as H3N2 influenza viruses. Finally, we show that vaccination with the older H1N1 viruses, particularly A/FM/1/47, confers protective immunity against the 2009 pandemic H1N1 virus. Taken together, our data provide an explanation for the decreased susceptibility of the elderly to the 2009 H1N1 outbreak and demonstrate that vaccination with the pre-1950 influenza strains can cross-protect against the pandemic swine-origin 2009 H1N1 influenza virus.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Strategies to alleviate original antigenic sin responses to influenza viruses

Jin Hyang Kim; William G. Davis; Suryaprakash Sambhara; Joshy Jacob

Original antigenic sin is a phenomenon wherein sequential exposure to closely related influenza virus variants reduces antibody (Ab) response to novel antigenic determinants in the second strain and, consequently, impairs the development of immune memory. This could pose a risk to the development of immune memory in persons previously infected with or vaccinated against influenza. Here, we explored strategies to overcome original antigenic sin responses in mice sequentially exposed to two closely related hemagglutinin 1 neuraminidase 1 (H1N1) influenza strains A/PR/8/34 and A/FM/1/47. We found that dendritic cell–activating adjuvants [Bordetella pertussis toxin (PT) or CpG ODN or a squalene-based oil-in-water nanoemulsion (NE)], upon administration during the second viral exposure, completely protected mice from a lethal challenge and enhanced neutralizing-Ab titers against the second virus. Interestingly, PT and NE adjuvants when administered during the first immunization even prevented original antigenic sin in subsequent immunization without any adjuvants. As an alternative to using adjuvants, we also found that repeated immunization with the second viral strain relieved the effects of original antigenic sin. Taken together, our studies provide at least three ways of overcoming original antigenic sin.


Current Topics in Microbiology and Immunology | 2009

DNA vaccines against influenza viruses.

Jin Hyang Kim; Joshy Jacob

As an attractive alternative to conventional vaccines, DNA vaccines play a critical role in inducing protection against several infectious diseases. In this review, we discuss the advantages that DNA vaccines offer in comparison to conventional protein-based vaccines. We discuss strategies to improve the potency and efficacy of DNA vaccines. Specifically, we focus on the potential use of DNA-based vaccines to elicit broad-spectrum humoral and cellular immunity against influenza virus. Finally, we discuss the advances made in the use of DNA vaccines to prevent avian H5N1 influenza.


Journal of Immunology | 2012

Rapid Differentiation of Monocytes into Type I IFN-Producing Myeloid Dendritic Cells as an Antiviral Strategy against Influenza Virus Infection

Weiping Cao; Andrew K. Taylor; Renata Biber; William G. Davis; Jin Hyang Kim; Adrian J. Reber; Tatiana Chirkova; Juan A. De La Cruz; Aseem Pandey; Priya Ranjan; Jacqueline M. Katz; Shivaprakash Gangappa; Suryaprakash Sambhara

Myeloid dendritic cells (mDCs) have long been thought to function as classical APCs for T cell responses. However, we demonstrate that influenza viruses induce rapid differentiation of human monocytes into mDCs. Unlike the classic mDCs, the virus-induced mDCs failed to upregulate DC maturation markers and were unable to induce allogeneic lymphoproliferation. Virus-induced mDCs secreted little, if any, proinflammatory cytokines; however, they secreted a substantial amount of chemoattractants for monocytes (MCP-1 and IP-10). Interestingly, the differentiated mDCs secreted type I IFN and upregulated the expression of IFN-stimulated genes (tetherin, IFITM3, and viperin), as well as cytosolic viral RNA sensors (RIG-I and MDA5). Additionally, culture supernatants from virus-induced mDCs suppressed the replication of virus in vitro. Furthermore, depletion of monocytes in a mouse model of influenza infection caused significant reduction of lung mDC numbers, as well as type I IFN production in the lung. Consequently, increased lung virus titer and higher mortality were observed. Taken together, our results demonstrate that the host responds to influenza virus infection by initiating rapid differentiation of circulating monocytes into IFN-producing mDCs, which contribute to innate antiviral immune responses.


Journal of Immunology | 2012

CD28–B7 Interaction Modulates Short- and Long-Lived Plasma Cell Function

Modesta N. Njau; Jin Hyang Kim; Craig P. Chappell; Rajesh Ravindran; Leela Thomas; Bali Pulendran; Joshy Jacob

The interaction of CD28, which is constitutively expressed on T cells, with B7.1/B7.2 expressed on APCs is critical for T cell activation. CD28 is also expressed on murine and human plasma cells but its function on these cells remains unclear. There are two types of plasma cells: short-lived ones that appear in the secondary lymphoid tissue shortly after Ag exposure, and long-lived plasma cells that mainly reside in the bone marrow. We demonstrate that CD28-deficient murine short- and long-lived plasma cells produce significantly higher levels of Abs than do their wild-type counterparts. This was owing to both increased frequencies of plasma cells as well as increased Ab production per plasma cell. Plasma cells also express the ligand for CD28, B7.1, and B7.2. Surprisingly, deficiency of B7.1 and B7.2 in B cells also led to higher Ab levels, analogous to Cd28−/− plasma cells. Collectively, our results suggest that the CD28–B7 interaction operates as a key modulator of plasma cell function.


Scientific Reports | 2017

Influenza virus exploits tunneling nanotubes for cell-to-cell spread.

Amrita Kumar; Jin Hyang Kim; Priya Ranjan; Maureen G. Metcalfe; Weiping Cao; Margarita Mishina; Shivaprakash Gangappa; Zhu Guo; Edward S. Boyden; Sherif R. Zaki; Ian A. York; Adolfo García-Sastre; Michael Shaw; Suryaprakash Sambhara

Tunneling nanotubes (TNTs) represent a novel route of intercellular communication. While previous work has shown that TNTs facilitate the exchange of viral or prion proteins from infected to naïve cells, it is not clear whether the viral genome is also transferred via this mechanism and further, whether transfer via this route can result in productive replication of the infectious agents in the recipient cell. Here we present evidence that lung epithelial cells are connected by TNTs, and in spite of the presence of neutralizing antibodies and an antiviral agent, Oseltamivir, influenza virus can exploit these networks to transfer viral proteins and genome from the infected to naïve cell, resulting in productive viral replication in the naïve cells. These observations indicate that influenza viruses can spread using these intercellular networks that connect epithelial cells, evading immune and antiviral defenses and provide an explanation for the incidence of influenza infections even in influenza-immune individuals and vaccine failures.


Expert Review of Vaccines | 2011

Improving immunogenicity and effectiveness of influenza vaccine in older adults

Weiping Cao; Jin Hyang Kim; Tatiana Chirkova; Adrian J. Reber; Renata Biber; David K. Shay; Suryaprakash Sambhara

Aging is associated with a decline in immune function (immunosenescence) that leads to progressive deterioration in both innate and adaptive immune functions. These changes contribute to the subsequent increased risk for infectious diseases and their sequelae. Vaccination is the most effective and inexpensive public health strategy for prevention of infection, despite the decreased efficacy of vaccines in older adults due to immunosenescence. The rapid rise in the older adult population globally represents a great challenge for vaccination programs. This article first addresses the status of innate and adaptive immune functions in aging and then focuses on influenza vaccine. The development history of influenza vaccines, current status, and potential strategies to improve the immunogenicity and vaccine effectiveness in older adults are discussed.


Open Forum Infectious Diseases | 2015

Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses

Adrian J. Reber; Jin Hyang Kim; Renata Biber; H. Keipp Talbot; Laura A. Coleman; Tatiana Chirkova; F. Liaini Gross; Evelene Steward-Clark; Weiping Cao; Stacie Jefferson; Vic Veguilla; Eric Gillis; Jennifer K. Meece; Yaohui Bai; Heather Tatum; Kathy Hancock; James Stevens; Sarah Spencer; Jufu Chen; Paul Gargiullo; Elise Braun; Marie R. Griffin; Maria E. Sundaram; Edward A. Belongia; David K. Shay; Jacqueline M. Katz; Suryaprakash Sambhara

Background.u2003Influenza disproportionately impacts older adults while current vaccines have reduced effectiveness in the older population. Methods.u2003We conducted a comprehensive evaluation of cellular and humoral immune responses of adults aged 50 years and older to the 2008–2009 seasonal trivalent inactivated influenza vaccine and assessed factors influencing vaccine response. Results.u2003Vaccination increased hemagglutination inhibition and neutralizing antibody; however, 66.3% of subjects did not reach hemagglutination inhibition titers ≥ 40 for H1N1, compared with 22.5% for H3N2. Increasing age had a minor negative impact on antibody responses, whereas prevaccination titers were the best predictors of postvaccination antibody levels. Preexisting memory B cells declined with age, especially for H3N2. However, older adults still demonstrated a significant increase in antigen-specific IgG+ and IgA+ memory B cells postvaccination. Despite reduced frequency of preexisting memory B cells associated with advanced age, fold-rise in memory B cell frequency in subjects 60+ was comparable to subjects age 50–59. Conclusions.u2003Older adults mounted statistically significant humoral and cell-mediated immune responses, but many failed to reach hemagglutination inhibition titers ≥40, especially for H1N1. Although age had a modest negative effect on vaccine responses, prevaccination titers were the best predictor of postvaccination antibody levels, irrespective of age.


Vaccine | 2016

Prior infection with influenza virus but not vaccination leaves a long-term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine strains

Jin Hyang Kim; Justine S. Liepkalns; Adrian J. Reber; Xiuhua Lu; Nedzad Music; Joshy Jacob; Suryaprakash Sambhara

The role of pre-existing immunity for influenza vaccine responses is of great importance for public health, and thus has been studied in various contexts, yet the impact of differential priming on vaccine responses in the midst of antigenic drift remains to be elucidated. To address this with antigenically related viruses, mice were first primed by either infection or immunization with A/Puerto Rico/8/34 (PR8) virus, then immunized with whole-inactivated A/Fort Monmouth/1/47 (FM1) virus. The ensuing vaccine responses and the protective efficacy of FM1 were superior in PR8 infection-primed mice compared to PR8 immunization-primed or unprimed mice. Increased FM1-specific Ab responses of PR8 infection-primed mice also broadened cross-reactivity against contemporary as well as antigenically more drifted strains. Further, prior infection heightened the protective efficacy of antigenically distant strains, such as A/Brisbane/59/2006 infection followed by immunization with split pandemic H1N1 vaccine (A/California/07/2009). Therefore, influenza infection is a significant priming event that intensifies future vaccine responses against drift strains.

Collaboration


Dive into the Jin Hyang Kim's collaboration.

Top Co-Authors

Avatar

Suryaprakash Sambhara

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Weiping Cao

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Adrian J. Reber

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shivaprakash Gangappa

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Jacqueline M. Katz

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Ian A. York

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Priya Ranjan

Oak Ridge National Laboratory

View shared research outputs
Top Co-Authors

Avatar

Amrita Kumar

National Center for Immunization and Respiratory Diseases

View shared research outputs
Top Co-Authors

Avatar

Margarita Mishina

Battelle Memorial Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge